Literature DB >> 16650368

[HIV entry into the cells--mechanisms and therapeutic possibilities].

Verónica Briz1, Eva Poveda, Vicente Soriano.   

Abstract

Human immunodeficiency virus (HIV) entry into cells is the first step in the viral replication cycle, which has been explored as a new therapeutic target. A better knowledge of the mechanisms involved in the entry process has led to the development of agents, which may inhibit each of the different steps of the viral entry process: attachment of the gp120 to the CD4 cell receptor; binding of the gp120 to CCR5 or CXCR4 coreceptors; and the fusion of viral and cell membranes. Entry inhibitors are the latest family of antiretroviral compounds, being enfuvirtide, a fusion inhibitor, the first approved. Several other entry inhibitors are currently in clinical development and hopefully soon will be part of the therapeutic armamentarium against HIV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650368      PMCID: PMC7131321          DOI: 10.1157/13085735

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  75 in total

Review 1.  The potential for HIV fusion inhibition.

Authors:  N Cammack
Journal:  Curr Opin Infect Dis       Date:  2001-02       Impact factor: 4.915

2.  Enfuvirtide is active against HIV type 1 group O.

Authors:  Eva Poveda; Pablo Barreiro; Berta Rodés; Vincent Soriano
Journal:  AIDS Res Hum Retroviruses       Date:  2005-06       Impact factor: 2.205

3.  Hypothetical assignment of intrachain disulfide bonds for HIV-2 and SIV envelope glycoproteins.

Authors:  J A Hoxie
Journal:  AIDS Res Hum Retroviruses       Date:  1991-06       Impact factor: 2.205

4.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

Authors:  G A Donzella; D Schols; S W Lin; J A Esté; K A Nagashima; P J Maddon; G P Allaway; T P Sakmar; G Henson; E De Clercq; J P Moore
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

5.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

6.  Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates.

Authors:  G P Allaway; K L Davis-Bruno; G A Beaudry; E B Garcia; E L Wong; A M Ryder; K W Hasel; M C Gauduin; R A Koup; J S McDougal
Journal:  AIDS Res Hum Retroviruses       Date:  1995-05       Impact factor: 2.205

7.  Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

Authors:  T Dragic; A Trkola; S W Lin; K A Nagashima; F Kajumo; L Zhao; W C Olson; L Wu; C R Mackay; G P Allaway; T P Sakmar; J P Moore; P J Maddon
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Molecular cloning and functional expression of a new human CC-chemokine receptor gene.

Authors:  M Samson; O Labbe; C Mollereau; G Vassart; M Parmentier
Journal:  Biochemistry       Date:  1996-03-19       Impact factor: 3.162

9.  Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

Authors:  Myriam Witvrouw; Christophe Pannecouque; William M Switzer; Thomas M Folks; Erik De Clercq; Walid Heneine
Journal:  Antivir Ther       Date:  2004-02

10.  Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy.

Authors:  Yossef Kliger; Erez Y Levanon
Journal:  BMC Microbiol       Date:  2003-09-21       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.